Carmen Calles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Carmen Calles has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Adrián Arés
Servicio de Neurología, Complejo Asistencial Universitario de León, 24008 León, España
4 shared publications - Alfredo Rodríguez-Antigüedad
Servicio de Neurología, Hospital Universitario Cruces, 48903 Barakaldo, España
4 shared publications - Ana Alonso
Unidad de Esclerosis Múltiple, Servicio de Neurología, Hospital Regional Universitario de Málaga, 29010 Málaga, España
4 shared publications - Ana Belén Caminero
Department of Neurology, Complejo Asistencial de Ávila
4 shared publications - Celia Oreja-Guevara
Hospital Clinico San Carlos, Madrid, Spain
4 shared publications - Eduardo Agüera
Servicio de Neurología, Hospital Reina Sofía, 14004 Córdoba, España
4 shared publications
Latest Publications
- Open Access
- 20 August 2026
- Published by IMR Press in Revista De Neurologia
- Vol. 81 (8)
XVIII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2025 ECTRIMS Congress (Part II)
The 18th edition of the post-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting was held on 17–18 October 2025 in Madrid, bringing together Spanish neurologists specialising in multiple sclerosis (MS), who presented the most relevant advances discussed at the ECTRIMS congress held a few days earlier in Barcelona. The aim of this edition was to present the latest developments in MS regarding the update of diagnostic criteria, advanced neuroimaging techniques, the role of Epstein-Barr virus, remyelination mechanisms and biomarkers. In the therapeutic field, emerging treatments were addressed, such as new monoclonal antibodies and chimeric antigen receptor T cells (CAR-T), the management of elderly patients and the risks associated with high-efficacy therapies. This article is the second of a two-part series (I and II). The article reviews recent data on disease progression and on the concept of progression independent of relapse activity (PIRA), including the definition, among those published, that leads to balanced incidence and persistence in PIRA rates. Certain neuropathological and imaging aspects are reviewed, and, with regard to serum biomarkers, it is emphasised that neurofilament light chain (NfL) is a marker of acute damage that is not specific to MS, and that the challenge lies in establishing a value that differentiates it from other diseases. It is also discussed whether the low sensitivity of NfL for predicting progression lies in the z-score used in clinical practice, and the usefulness of glial fibrillary acidic protein (GFAP) in combination with NfL to refine the assessment of chronic progressive damage. The importance of age in MS is indisputable. The elderly patient with MS has a greater number of comorbidities and is more vulnerable to certain treatments. Menopause is a normal but expected physiological transition of female ageing that may trigger or aggravate certain health problems, and whose symptoms should not be confused with worsening of the disease. As for cognitive impairment in MS, the latest developments and expert opinions that could help improve its identification and monitoring are summarised. Much of this part II article focuses on summarising the key advances in emerging therapies and treatment prospects in related diseases, without overlooking the risks associated with very high-efficacy therapies and the possible risk-prevention strategies. Finally, as important findings that translate into clinical practice, the notable improvement in diagnosis with the new 2024 McDonald criteria stands out, despite the barriers to accessing paraclinical tests in certain populations. Overall, the data reviewed, together with those gathered in part I, reflect the research effort to advance the understanding of the disease from multiple complementary perspectives, which is transforming the care of patients with MS.
- 20 August 2026
- Published by IMR Press in Revista De Neurologia
- Vol. 81 (8)
Open AccessXVIII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2025 ECTRIMS Congress (Part II)
The 18th edition of the post-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting was held on 17–18 October 2025 in Madrid, bringing together Spanish neurologists specialising in multiple sclerosis (MS), who presented the most relevant advances discussed at the ECTRIMS congress held a few days earlier in Barcelona. The aim of this edition was to present the latest developments in MS regarding the update of diagnostic criteria, advanced neuroimaging techniques, the role of Epstein-Barr virus, remyelination mechanisms and biomarkers. In the therapeutic field, emerging treatments were addressed, such as new monoclonal antibodies and chimeric antigen receptor T cells (CAR-T), the management of elderly patients and the risks associated with high-efficacy therapies. This article is the second of a two-part series (I and II). The article reviews recent data on disease progression and on the concept of progression independent of relapse activity (PIRA), including the definition, among those published, that leads to balanced incidence and persistence in PIRA rates. Certain neuropathological and imaging aspects are reviewed, and, with regard to serum biomarkers, it is emphasised that neurofilament light chain (NfL) is a marker of acute damage that is not specific to MS, and that the challenge lies in establishing a value that differentiates it from other diseases. It is also discussed whether the low sensitivity of NfL for predicting progression lies in the z-score used in clinical practice, and the usefulness of glial fibrillary acidic protein (GFAP) in combination with NfL to refine the assessment of chronic progressive damage. The importance of age in MS is indisputable. The elderly patient with MS has a greater number of comorbidities and is more vulnerable to certain treatments. Menopause is a normal but expected physiological transition of female ageing that may trigger or aggravate certain health problems, and whose symptoms should not be confused with worsening of the disease. As for cognitive impairment in MS, the latest developments and expert opinions that could help improve its identification and monitoring are summarised. Much of this part II article focuses on summarising the key advances in emerging therapies and treatment prospects in related diseases, without overlooking the risks associated with very high-efficacy therapies and the possible risk-prevention strategies. Finally, as important findings that translate into clinical practice, the notable improvement in diagnosis with the new 2024 McDonald criteria stands out, despite the barriers to accessing paraclinical tests in certain populations. Overall, the data reviewed, together with those gathered in part I, reflect the research effort to advance the understanding of the disease from multiple complementary perspectives, which is transforming the care of patients with MS.
- Open Access
- 14 August 2026
- Published by IMR Press in Revista De Neurologia
- Vol. 81 (8)
XVIII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2025 ECTRIMS Congress (Part I)
The 18th edition of the post-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting was held on 17–18 October 2025 in Madrid, bringing together Spanish neurologists specialising in multiple sclerosis (MS), who presented the most relevant advances discussed at the ECTRIMS congress held a few days earlier in Barcelona. The aim of the meeting was to summarise the latest developments in the pathogenesis, new diagnostic criteria and biomarkers of MS. This article is the first of a two-part series (I and II) that reviews recent data on cell trafficking into the central nervous system, highlighting the functional heterogeneity of the brain endothelium, the molecular mechanisms regulating leukocyte infiltration and the differential role of macrophages and resident microglia in tissue damage and chronic inflammation. The evidence supporting the role of Epstein-Barr virus as a necessary risk factor in MS is presented, together with the therapeutic and preventive implications from studies of antiviral therapies, cell-based therapies and vaccines. Regarding diagnosis, the new criteria for neuromyelitis optica spectrum disorders are addressed, with particular attention to the molecular heterogeneity of double-seronegative forms, as well as the update of the magnetic resonance imaging (MRI) guidelines following the 2024 revision of the McDonald criteria. Advances in the neuroimaging of chronic active inflammation, quantitative spinal cord imaging and the concept of spinal cord reserve are highlighted. The growing role of artificial intelligence applied to MRI for the early prediction of progression and treatment response is also reviewed. Finally, advances in remyelination mechanisms and in biomarkers are presented, underscoring the value of multimodal and longitudinal approaches for prognostic stratification and treatment monitoring. Overall, the data reviewed reflect a change into a more integrated and predictive understanding of MS, with direct implications for early diagnosis, treatment personalisation and the design of future clinical trials.
- 14 August 2026
- Published by IMR Press in Revista De Neurologia
- Vol. 81 (8)
Open AccessXVIII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2025 ECTRIMS Congress (Part I)
The 18th edition of the post-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting was held on 17–18 October 2025 in Madrid, bringing together Spanish neurologists specialising in multiple sclerosis (MS), who presented the most relevant advances discussed at the ECTRIMS congress held a few days earlier in Barcelona. The aim of the meeting was to summarise the latest developments in the pathogenesis, new diagnostic criteria and biomarkers of MS. This article is the first of a two-part series (I and II) that reviews recent data on cell trafficking into the central nervous system, highlighting the functional heterogeneity of the brain endothelium, the molecular mechanisms regulating leukocyte infiltration and the differential role of macrophages and resident microglia in tissue damage and chronic inflammation. The evidence supporting the role of Epstein-Barr virus as a necessary risk factor in MS is presented, together with the therapeutic and preventive implications from studies of antiviral therapies, cell-based therapies and vaccines. Regarding diagnosis, the new criteria for neuromyelitis optica spectrum disorders are addressed, with particular attention to the molecular heterogeneity of double-seronegative forms, as well as the update of the magnetic resonance imaging (MRI) guidelines following the 2024 revision of the McDonald criteria. Advances in the neuroimaging of chronic active inflammation, quantitative spinal cord imaging and the concept of spinal cord reserve are highlighted. The growing role of artificial intelligence applied to MRI for the early prediction of progression and treatment response is also reviewed. Finally, advances in remyelination mechanisms and in biomarkers are presented, underscoring the value of multimodal and longitudinal approaches for prognostic stratification and treatment monitoring. Overall, the data reviewed reflect a change into a more integrated and predictive understanding of MS, with direct implications for early diagnosis, treatment personalisation and the design of future clinical trials.
- Open Access
- 21 January 2026
- Published by IMR Press in Revista De Neurologia
- Vol. 81 (1) , 39227
XVII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2024 ECTRIMS Congress (I)
Introduction: The XVII edition of the post-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting was held on 4–5 October 2024 in Madrid. This event was attended by Spanish neurologists specialized in multiple sclerosis (MS), who presented a summary of the most relevant advances discussed at the ECTRIMS congress, held days before in Copenhagen. Aim: To present new developments in neurodegeneration and progression, the prodromal phase and diagnosis, the clinical use of biomarkers and neuroimaging, as well as the current role of patient-reported outcomes and digital monitoring. Highlights on the risk of infections and comorbidities in MS are also summarized. Content and Conclusions: In active MS lesions, there is no correlation between the myeloid cell phenotype and remyelination, while memory astrocytes, regulated by the CLEC16A gene, are present in chronic active lesions. Gray matter atrophy is associated with disability and progression independent of relapses, whereas cervical spinal cord atrophy predicts the prognosis of progressive forms and may lead to earlier diagnosis. Healthcare resource utilization increases in the years preceding the first demyelinating event, and although prodromal symptoms are highly variable, they are useful in identifying risk factors for the disease. The new McDonald criteria will facilitate the diagnosis of MS in patients with a radiologically isolated syndrome. Glial fibrillary acidic protein complements neurofilaments, and both biomarkers could soon be standardized for use in clinical practice; paramagnetic rim lesions and slowly expanding lesions are promising imaging markers. In another area, patient-reported health outcomes are valuable, although they are subject to selection bias and the need to define boundaries for their use. Finally, the risk of infections increases before diagnosis and may worsen with certain treatments. Comorbidities in MS should be managed as an integral part of disease management.
- 21 January 2026
- Published by IMR Press in Revista De Neurologia
- Vol. 81 (1) , 39227
Open AccessXVII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2024 ECTRIMS Congress (I)
Introduction: The XVII edition of the post-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting was held on 4–5 October 2024 in Madrid. This event was attended by Spanish neurologists specialized in multiple sclerosis (MS), who presented a summary of the most relevant advances discussed at the ECTRIMS congress, held days before in Copenhagen. Aim: To present new developments in neurodegeneration and progression, the prodromal phase and diagnosis, the clinical use of biomarkers and neuroimaging, as well as the current role of patient-reported outcomes and digital monitoring. Highlights on the risk of infections and comorbidities in MS are also summarized. Content and Conclusions: In active MS lesions, there is no correlation between the myeloid cell phenotype and remyelination, while memory astrocytes, regulated by the CLEC16A gene, are present in chronic active lesions. Gray matter atrophy is associated with disability and progression independent of relapses, whereas cervical spinal cord atrophy predicts the prognosis of progressive forms and may lead to earlier diagnosis. Healthcare resource utilization increases in the years preceding the first demyelinating event, and although prodromal symptoms are highly variable, they are useful in identifying risk factors for the disease. The new McDonald criteria will facilitate the diagnosis of MS in patients with a radiologically isolated syndrome. Glial fibrillary acidic protein complements neurofilaments, and both biomarkers could soon be standardized for use in clinical practice; paramagnetic rim lesions and slowly expanding lesions are promising imaging markers. In another area, patient-reported health outcomes are valuable, although they are subject to selection bias and the need to define boundaries for their use. Finally, the risk of infections increases before diagnosis and may worsen with certain treatments. Comorbidities in MS should be managed as an integral part of disease management.
- Open Access
- 21 January 2026
- Published by IMR Press in Revista De Neurologia
- Vol. 81 (1) , 39228
XVII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2024 ECTRIMS Congress (II)
Introduction: The XVII edition of the post-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting was held on 4–5 October 2024 in Madrid. This event was attended by Spanish neurologists specialized in multiple sclerosis (MS), who presented a summary of the most relevant advances discussed at the ECTRIMS congress, held days before in Copenhagen. Aim: To summarize the main new findings in clinical research on MS. Content and Conclusions: The immunological changes throughout life and in response to MS treatments were analyzed. The impact of aging was also discussed, along with new developments related to symptomatic treatments, physical exercise, fatigue, and sleep disorders. Emphasis was placed on addressing ongoing challenges in measuring therapeutic failure and managing treatments for secondary progressive MS. Additionally, data from registries and real-world studies were presented, including new analyses on cladribine, highlighting the need to collect safety information. Regarding immune reconstitution therapies, mechanisms of action and the immune system’s reconstitution process after treatment were explored. Finally, regarding therapeutic innovations, the first results from chimeric antigen receptor (CAR)-T cell therapy studies in MS were reported, representing a promising advancement in disease management.
- 21 January 2026
- Published by IMR Press in Revista De Neurologia
- Vol. 81 (1) , 39228
Open AccessXVII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2024 ECTRIMS Congress (II)
Introduction: The XVII edition of the post-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting was held on 4–5 October 2024 in Madrid. This event was attended by Spanish neurologists specialized in multiple sclerosis (MS), who presented a summary of the most relevant advances discussed at the ECTRIMS congress, held days before in Copenhagen. Aim: To summarize the main new findings in clinical research on MS. Content and Conclusions: The immunological changes throughout life and in response to MS treatments were analyzed. The impact of aging was also discussed, along with new developments related to symptomatic treatments, physical exercise, fatigue, and sleep disorders. Emphasis was placed on addressing ongoing challenges in measuring therapeutic failure and managing treatments for secondary progressive MS. Additionally, data from registries and real-world studies were presented, including new analyses on cladribine, highlighting the need to collect safety information. Regarding immune reconstitution therapies, mechanisms of action and the immune system’s reconstitution process after treatment were explored. Finally, regarding therapeutic innovations, the first results from chimeric antigen receptor (CAR)-T cell therapy studies in MS were reported, representing a promising advancement in disease management.